Oxcarbazepine Shortage: What Providers and Prescribers Need to Know in 2026

This briefing is intended for neurologists, epileptologists, psychiatrists, and primary care physicians who prescribe Oxcarbazepine (brand: Trileptal; extended-release: Oxtellar XR). It covers the current supply landscape, prescribing implications, clinical strategies for navigating access issues, and resources to help your patients maintain consistent medication access.

Current Supply Status (Early 2026)

Oxcarbazepine is not currently listed on the FDA Drug Shortage Database or the ASHP shortage list. However, clinicians across the country continue to receive calls from patients who cannot fill their prescriptions at their usual pharmacy. Key availability facts:

• FDA/ASHP status: No official shortage as of early 2026
• Affected formulations: 600 mg IR tablets and oral suspension (300 mg/5 mL) most frequently reported as unavailable
• Brand Trileptal: Limited retail distribution; most prescriptions filled with generic
• Oxtellar XR: Generally available through specialty distributors; may require ordering at some retail pharmacies
• Generic IR tablets (150 mg, 300 mg): Most consistently available; distribution remains stable with multiple manufacturers

Supply Chain Context

The intermittent availability issues reflect a systemic problem in the generic drug supply chain rather than a drug-specific crisis. Key contributing factors:

• COVID-era disruptions (2020–2022) that permanently reduced inventory buffer capacity at multiple points in the supply chain
• Thin margins on generic AEDs reducing manufacturer motivation to hold large safety stocks
• Quality control inspections leading to temporary production pauses at individual facilities
• Just-in-time ordering at retail pharmacy chains amplifying regional disruptions

Clinical Prescribing Strategies

The following strategies can help minimize the impact of availability disruptions on your patients:

1. Write for Multiple Strengths When Clinically Appropriate

Generic Oxcarbazepine IR tablets can be substituted at equal doses. A patient prescribed 600 mg BID can use two 300 mg tablets per dose if the 600 mg tablet is unavailable. Consider writing prescriptions that allow for lower-strength substitution at the pharmacist level, or proactively note this on the prescription.

2. Consider the Oral Suspension as a Backup for Pediatric Patients

The oral suspension (300 mg/5 mL) is a direct dose-equivalent to tablets and uses a different supply chain. When tablets are unavailable, the suspension may be a viable bridge — particularly for pediatric patients or those with swallowing difficulties. Note that storage requirements differ: the suspension should be stored at room temperature and used within 7 weeks of opening.

3. Discuss Mail-Order Pharmacy with Stable Patients

Patients on stable doses of Oxcarbazepine are ideal candidates for mail-order pharmacy. Mail-order pharmacies maintain larger inventory and are less susceptible to the day-to-day fluctuations affecting retail locations. A 90-day supply via mail-order also reduces the frequency of potential refill disruptions.

Therapeutic Alternatives to Consider

If Oxcarbazepine is consistently unavailable for a patient, the following alternatives merit consideration based on seizure type, comorbidities, and drug interaction profile:

• Carbamazepine (Tegretol): Pharmacologically closest; same mechanism; requires CBC/LFT monitoring and HLA-B*1502 screening in Asian patients; significant CYP3A4 induction
• Eslicarbazepine (Aptiom): Same chemical family; once-daily dosing; fewer drug interactions than Carbamazepine; brand-only or limited generic with higher cost
• Lamotrigine (Lamictal): Different mechanism; requires slow titration over 8–12 weeks; effective for focal and generalized seizures and bipolar maintenance; widely available generic
• Levetiracetam (Keppra): Different mechanism (SV2A modulator); no hepatic metabolism; minimal drug interactions; does not affect OCP efficacy; behavioral side effects in some patients

Hyponatremia: A Monitoring Note

Regardless of availability issues, remind patients and staff that Oxcarbazepine carries a clinically significant hyponatremia risk. Approximately 2–3% of patients develop serum sodium below 125 mmol/L, with the highest risk in the first 3 months of therapy. The risk is elevated in elderly patients and those on diuretics. Routine sodium monitoring is recommended, particularly during initiation and titration.

Resources for Your Patients

When patients call your office unable to fill their Oxcarbazepine prescription, direct them to medfinder for Providers. medfinder calls pharmacies near the patient to check which ones can fill the prescription — saving your staff from hours of phone coordination. Results are texted directly to the patient.

For a step-by-step guide to helping patients locate their medication, see how to help your patients find Oxcarbazepine in stock.